NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

It's interesting, I think, that Conditional Survival is one of the analyses they will be making in the primary endpoint.

I had to look it up to see what it actually meant, and what it measured. It seems that they will be examining at the patients' odds of living to a certain point, if they've lived already to another point.

For example, if you've lived to 3 years on treatment, what, then, is your probability of surviving to 4 and 5 years? And if you've lived to 5 years, what is the survival probability of living to, say, 7 or 10 years?

I'd think those percentages wouldn't look so good for the vast number of patients from the external control arm pool. So one should consider why Northwest would have decided to include this measurement when looking at those treatment arm patients who'd received the early DCVax-L treatment? Certainly we know from LL that in 2018, those top 100 patients had moved up their median from the early 2017 blinded, blended data from 40.5 to and impressive 58.4 months. Given those figures, it makes sense, I think, to have made conditional survival a measurement, as that ought to add to the beefiness of the primary endpoint for DCVax-L.

I'd bet those aren't usually measured for GBM treatment, because prior to DCVax-L, conditional survival would have presented as being so terribly dismal, so what would the point be?